Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Insulin degludec shows promise in diabetes

Self-administration of daily insulin degludag injections is no less effective than self-injecting insulin glargine in patients with diabetes who are new to insulin therapy, say researchers.

4 Oct 2012

Merck announces data from MK-3102 Phase IIb trial on type 2 diabetes

Merck, known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes.

4 Oct 2012

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.

3 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

2 Oct 2012

Low blood sugar danger for critically ill

Further analysis of the NICE-SUGAR trial shows a dose‑response relationship between the degree of hypoglycemia and the risk for death in critically ill patients.

25 Sep 2012

Extended release exenatide outperforms twice daily regimen

Once-weekly extended-release exenatide is a more effective treatment than twice-daily exenatide at improving glucose control among Japanese individuals with diabetes, report researchers.

24 Sep 2012

Tight glycemic control does not reduce infection rate after pediatric cardiac surgery

Implementing tight glycemic control after surgery with cardiopulmonary bypass does not reduce the rate of healthcare-associated infections among pediatric patients, compared with standard care in the intensive care unit, show US study results.

20 Sep 2012

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announce the availability of a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health.

14 Sep 2012

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.

13 Sep 2012

Tight blood sugar control does not benefit pediatric patients undergoing heart surgery

Although some studies have portrayed tight blood sugar control as a potential means of lowering infection rates in critically ill adults, a new study-led by principal investigator Michael Agus, MD, director of the Medicine Critical Care Program at Boston Children's Hospital-found no indication that the approach benefits pediatric patients undergoing heart surgery.

10 Sep 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Investigational drug shows promise against most severe form of congenital hyperinsulinism

A pilot study in adolescents and adults has found that an investigational drug shows promise as the first potential medical treatment for children with the severest type of congenital hyperinsulinism, a rare but potentially devastating disease in which gene mutations cause insulin levels to become dangerously high.

2 Aug 2012

Long-term linagliptin effective treatment for Type 2 diabetes

Linagliptin is an effective and well-tolerated therapy for the long-term management of Type 2 diabetes, say the authors of an open-label extension study published in the International Journal of Clinical Practice.

27 Jul 2012

New blood sugar monitor: An interview with Sherita Hill Golden

Type 1 diabetes is a disorder in which the body makes proteins (antibodies) against the cells in the pancreas that produce insulin, destroying those cells. As a result, individuals are unable to secrete insulin to normalize blood sugar and hyperglycemia results.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

Two-drug combo increases diabetes patients’ goal achievement

Post-hoc analysis of randomized trial results shows that treating individuals with Type 2 diabetes with a combination of phentermine and topiramate increases their achievement of goals recommended for the management of their condition.

10 Jul 2012

New devices effectively monitor and control blood sugar levels in people with diabetes

Newer technologies designed to help people with type 1 diabetes monitor their blood sugar levels daily work better than traditional methods and require fewer painful needle sticks, new Johns Hopkins research suggests.

10 Jul 2012

New blood sugar monitor works better than conventional methods

10 Jul 2012

Cintas launches blood sugar control product for first-aid cabinets

Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.

9 Jul 2012

Hypoglycemia News and Research

Further Reading

Insulin degludec shows promise in diabetes

Merck announces data from MK-3102 Phase IIb trial on type 2 diabetes

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

One rule for one and one for another with diabetes

Low blood sugar danger for critically ill

Extended release exenatide outperforms twice daily regimen

Tight glycemic control does not reduce infection rate after pediatric cardiac surgery

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Tight blood sugar control does not benefit pediatric patients undergoing heart surgery

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Investigational drug shows promise against most severe form of congenital hyperinsulinism

Long-term linagliptin effective treatment for Type 2 diabetes

New blood sugar monitor: An interview with Sherita Hill Golden

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Arena files lorcaserin hydrochloride MAA with Swissmedic

Two-drug combo increases diabetes patients’ goal achievement

New devices effectively monitor and control blood sugar levels in people with diabetes

New blood sugar monitor works better than conventional methods

Cintas launches blood sugar control product for first-aid cabinets

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News